JP2004534839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534839A5 JP2004534839A5 JP2003511754A JP2003511754A JP2004534839A5 JP 2004534839 A5 JP2004534839 A5 JP 2004534839A5 JP 2003511754 A JP2003511754 A JP 2003511754A JP 2003511754 A JP2003511754 A JP 2003511754A JP 2004534839 A5 JP2004534839 A5 JP 2004534839A5
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- adjusting
- pharmaceutical composition
- dosage form
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims description 66
- 239000002253 acid Substances 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 238000010979 pH adjustment Methods 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 43
- 238000000034 method Methods 0.000 claims 38
- 239000002552 dosage form Substances 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000011248 coating agent Substances 0.000 claims 23
- 238000000576 coating method Methods 0.000 claims 23
- 238000010521 absorption reaction Methods 0.000 claims 19
- 238000004090 dissolution Methods 0.000 claims 15
- 239000012528 membrane Substances 0.000 claims 10
- 239000011159 matrix material Substances 0.000 claims 9
- 230000001737 promoting effect Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 230000002093 peripheral effect Effects 0.000 claims 7
- 238000013270 controlled release Methods 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
- 230000000202 analgesic effect Effects 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 230000002686 anti-diuretic effect Effects 0.000 claims 3
- 230000001387 anti-histamine Effects 0.000 claims 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 230000001754 anti-pyretic effect Effects 0.000 claims 3
- 229940124538 antidiuretic agent Drugs 0.000 claims 3
- 239000003160 antidiuretic agent Substances 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 claims 3
- 229940030600 antihypertensive agent Drugs 0.000 claims 3
- 239000002220 antihypertensive agent Substances 0.000 claims 3
- 239000002221 antipyretic Substances 0.000 claims 3
- 239000002830 appetite depressant Substances 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 239000000812 cholinergic antagonist Substances 0.000 claims 3
- 239000000850 decongestant Substances 0.000 claims 3
- 229940124581 decongestants Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 210000000936 intestine Anatomy 0.000 claims 3
- 239000008141 laxative Substances 0.000 claims 3
- 230000002475 laxative effect Effects 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229940125723 sedative agent Drugs 0.000 claims 3
- 239000000932 sedative agent Substances 0.000 claims 3
- 230000002048 spasmolytic effect Effects 0.000 claims 3
- 239000003204 tranquilizing agent Substances 0.000 claims 3
- 230000002936 tranquilizing effect Effects 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000003364 biologic glue Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 150000007513 acids Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/901,983 US20030068356A1 (en) | 2001-07-10 | 2001-07-10 | Sequential drug delivery systems |
| PCT/US2002/021796 WO2003005944A1 (en) | 2001-07-10 | 2002-07-10 | Sequential drug delivery systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534839A JP2004534839A (ja) | 2004-11-18 |
| JP2004534839A5 true JP2004534839A5 (enExample) | 2009-08-06 |
| JP4617081B2 JP4617081B2 (ja) | 2011-01-19 |
Family
ID=25415151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003511754A Expired - Fee Related JP4617081B2 (ja) | 2001-07-10 | 2002-07-10 | 連続的薬剤送達システム |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20030068356A1 (enExample) |
| EP (2) | EP1818029B1 (enExample) |
| JP (1) | JP4617081B2 (enExample) |
| AT (1) | ATE363261T1 (enExample) |
| AU (2) | AU2002320385B2 (enExample) |
| CA (1) | CA2451106C (enExample) |
| DE (1) | DE60220408T2 (enExample) |
| DK (1) | DK1406568T3 (enExample) |
| ES (2) | ES2286263T3 (enExample) |
| WO (1) | WO2003005944A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
| EP1449525A1 (en) * | 2003-02-20 | 2004-08-25 | Cross Chem Llc | chewing gum in the form of multi-layer tablets |
| KR100767271B1 (ko) * | 2003-07-11 | 2007-10-17 | 에프. 호프만-라 로슈 아게 | 사퀴나비르 메실레이트 경구 투여 형태 |
| UA81335C2 (uk) * | 2003-07-11 | 2007-12-25 | Ф.Хоффманн-Ля Рош Аг | Оральна дозована форма саквінавіру мезилату |
| CN1819821B (zh) | 2003-08-08 | 2010-10-13 | 拜奥维尔实验室国际股份有限公司 | 盐酸安非他酮的改良释放片剂 |
| WO2005065317A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| KR101184138B1 (ko) | 2003-12-31 | 2012-09-19 | 시마 랩스 인크. | 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법 |
| NZ548215A (en) * | 2003-12-31 | 2009-08-28 | Cima Labs Inc | Effervescent oral opiate dosage form |
| KR20070030178A (ko) * | 2004-02-17 | 2007-03-15 | 트랜스오랄 파마슈티칼스, 인코포레이티드 | 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법 |
| US7615028B2 (en) * | 2004-12-03 | 2009-11-10 | Chf Solutions Inc. | Extracorporeal blood treatment and system having reversible blood pumps |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| US20070287740A1 (en) | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
| BRPI0609984A2 (pt) * | 2005-05-25 | 2010-05-18 | Transcept Pharmaceuticals Inc | uso de zolpidem ou um sal do mesmo |
| US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| US20110009692A1 (en) * | 2007-12-26 | 2011-01-13 | Yossi Gross | Nitric oxide generation to treat female sexual dysfunction |
| US20090198271A1 (en) * | 2008-01-31 | 2009-08-06 | Rainbow Medical Ltd. | Electrode based filter |
| KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| WO2010118232A1 (en) * | 2009-04-09 | 2010-10-14 | Elan Pharma International Limited | Controlled-release clozapine compositions |
| PT2952191T (pt) | 2009-06-12 | 2018-11-30 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
| MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
| WO2011025673A1 (en) * | 2009-08-26 | 2011-03-03 | Aptapharma, Inc. | Multilayer minitablets |
| US20110202108A1 (en) * | 2010-02-18 | 2011-08-18 | Rainbow Medical Ltd. | Electrical menorrhagia treatment |
| US8529914B2 (en) * | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| EP2651357B1 (en) | 2010-12-16 | 2020-04-01 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| ME02153B (me) | 2011-09-19 | 2015-10-20 | Orexo Ab | Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida |
| US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| HUE064694T2 (hu) | 2012-03-22 | 2024-04-28 | Novo Nordisk As | Továbbítószert tartalmazó készítmények és elõállításuk |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| EP2830599B1 (en) | 2012-03-29 | 2018-08-15 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| HRP20161634T1 (hr) | 2012-05-02 | 2017-01-13 | Orexo Ab | Novi pripravak alfentanila za liječenje akutne boli |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| BR112017013311B1 (pt) | 2014-12-23 | 2022-05-31 | Acelrx Pharmaceuticals, Inc | Aparelho para a dispensação de formas de dosagem via oral e transmucosal |
| CA3127926A1 (en) | 2015-04-21 | 2016-10-27 | Sunovion Pharmaceuticals Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| US4756710A (en) | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
| US4764375A (en) | 1985-09-11 | 1988-08-16 | Kv Pharmaceutical Company | Sachet drug delivery system |
| GB8820327D0 (en) * | 1988-08-26 | 1988-09-28 | May & Baker Ltd | New compositions of matter |
| DE3838431A1 (de) * | 1988-11-12 | 1990-05-17 | Bayer Ag | Ibuprofen-brausezubereitungen |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| EP0737473A1 (en) * | 1989-10-02 | 1996-10-16 | Cima Labs, Inc. | Effervescent dosage form |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5102666A (en) * | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| TW212139B (enExample) * | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| IT1270831B (it) | 1993-09-17 | 1997-05-13 | Romano Deghenghi | Composizioni farmaceutiche orali effervescenti contenenti estrone |
| JP3021661B2 (ja) * | 1994-03-07 | 2000-03-15 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| DE69535127T2 (de) * | 1994-03-18 | 2007-02-15 | Supernus Pharmaceuticals, Inc. | Emulgierte arzneistoffabgabesysteme |
| JP3170139B2 (ja) | 1994-04-08 | 2001-05-28 | エスエス製薬株式会社 | 発泡性錠剤 |
| AU1958295A (en) * | 1994-04-13 | 1995-11-10 | Novartis Ag | Temporally controlled drug delivery systems |
| NZ288185A (en) | 1994-06-15 | 1998-02-26 | Dumex Alpharma As | Particulate pharmaceutical formulation containing coated cores comprising at least 80% of an inert carrier having a friability of <20%; the inert carrier can be calcium carbonate |
| GB9417524D0 (en) * | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| CA2160423A1 (en) * | 1994-11-02 | 1996-05-03 | Hemant N. Joshi | Salts of nefazodone having improved dissolution rates |
| FR2732217B1 (fr) * | 1995-03-29 | 1997-06-06 | Hesnard Xavier | Forme d'administration solide a usage oral |
| GB9510830D0 (en) * | 1995-05-27 | 1995-07-19 | Zeneca Ltd | Proteins |
| US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
| GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| CA2236368C (en) * | 1995-11-06 | 2001-10-23 | Somerset Pharmaceuticals, Inc. | Sublingual and buccal administration of selegiline |
| KR20010041696A (ko) | 1998-03-11 | 2001-05-25 | 그레랑 파마수티컬 가부시키가이샤 | 발포성 장용(腸溶) 제제 |
| US6200604B1 (en) * | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| DE19814257A1 (de) | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Brauseformulierungen |
| US6312728B1 (en) * | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
| JP4815053B2 (ja) | 1998-08-13 | 2011-11-16 | シーマ・ラブス、インコーポレイテッド | 経口投与の固形投与形態物としてのマイクロエマルション |
| WO2000035418A2 (en) * | 1998-12-18 | 2000-06-22 | Bayer Corporation | Chewable drug delivery system |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| US6326384B1 (en) * | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| KR101184138B1 (ko) * | 2003-12-31 | 2012-09-19 | 시마 랩스 인크. | 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법 |
| WO2005065317A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Effervescent oral fentanyl dosage form |
| NZ548215A (en) * | 2003-12-31 | 2009-08-28 | Cima Labs Inc | Effervescent oral opiate dosage form |
| US20070036853A1 (en) * | 2003-12-31 | 2007-02-15 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
-
2001
- 2001-07-10 US US09/901,983 patent/US20030068356A1/en not_active Abandoned
-
2002
- 2002-07-10 WO PCT/US2002/021796 patent/WO2003005944A1/en not_active Ceased
- 2002-07-10 AT AT02749899T patent/ATE363261T1/de active
- 2002-07-10 EP EP07006505.7A patent/EP1818029B1/en not_active Expired - Lifetime
- 2002-07-10 CA CA002451106A patent/CA2451106C/en not_active Expired - Fee Related
- 2002-07-10 ES ES02749899T patent/ES2286263T3/es not_active Expired - Lifetime
- 2002-07-10 ES ES07006505.7T patent/ES2604780T3/es not_active Expired - Lifetime
- 2002-07-10 DK DK02749899T patent/DK1406568T3/da active
- 2002-07-10 JP JP2003511754A patent/JP4617081B2/ja not_active Expired - Fee Related
- 2002-07-10 EP EP02749899A patent/EP1406568B1/en not_active Expired - Lifetime
- 2002-07-10 AU AU2002320385A patent/AU2002320385B2/en not_active Ceased
- 2002-07-10 DE DE60220408T patent/DE60220408T2/de not_active Expired - Lifetime
-
2003
- 2003-07-18 US US10/623,069 patent/US20030232080A1/en not_active Abandoned
-
2004
- 2004-09-08 US US10/936,185 patent/US7670617B2/en not_active Expired - Fee Related
-
2008
- 2008-08-01 AU AU2008203464A patent/AU2008203464B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2316316C2 (ru) | Плоский или пластинчатый лекарственный препарат с исправленным вкусом | |
| RU2403043C2 (ru) | Подъязычная таблетка, покрытая оболочкой | |
| JP4617081B2 (ja) | 連続的薬剤送達システム | |
| ES2534262T3 (es) | Comprimidos sublinguales de dosis baja de analgésicos opioides y proceso de preparación | |
| RU2460519C2 (ru) | Биоразрушаемый пластырь | |
| JP2002540141A5 (enExample) | ||
| JP2009535397A (ja) | 経粘膜的組成物 | |
| AU2010204986A1 (en) | Transdermal administration of tamsulosin | |
| CN104189913A (zh) | 包含聚乙烯醇-聚乙二醇接枝共聚物的泡沫干胶片 | |
| MX2009002041A (es) | Formulaciones galenicas de aliskiren. | |
| JP2011515485A (ja) | ロフェキシジンを経粘膜送達するための組成物およびその方法 | |
| ZA200706640B (en) | Method for a treatment with a medicament combination and medicament combinations suitable for the same | |
| JP2024156672A (ja) | 透過エンハンサーを含む送達医薬組成物 | |
| CZ289395A3 (en) | Transdermic therapeutic system for administration of serotonin agonists | |
| JP2024540936A (ja) | 増大された安定性プロファイルを有する医薬組成物 | |
| WO2008065144A2 (en) | Galenic formulations of organic compounds | |
| CA2546950A1 (en) | Oral formulations of desoxypeganine and uses thereof | |
| JP2007509031A (ja) | ガランタミンの口腔用製剤およびその使用 | |
| Zimmer et al. | Noninvasive drug delivery | |
| ES2235523T3 (es) | Empleo de esteres de testosterona y/o de testoterona para la produccion de sistemas bioadhesivos de aplicacion bucal con accion temporizada del medicamento. | |
| WO2025147530A1 (en) | Naloxone buccal film product and uses thereof | |
| HK1109730B (en) | Sublingual coated tablet |